Development of the Brussels Infant and Toddler Stool Scale ('BITSS'): protocol of the study

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Vandenplas Y
- Szajewska H
- Benninga M
- Di Lorenzo C
- Dupont C
- Faure C
- Miqdadi M
- Osatakul S
- Saps M
- Shamir R
- Staiano A
- BITSS Study Group
Grups d'Investigació
Abstract
Introduction: The Bristol Stool Form Scale (BSS) which consists of 7 photographs of different stool forms allows assessment of stool consistency (scale 1 for hard lumps to scale 7 for watery stools), in an objective manner in adults. The BSS is also sometimes used to characterise the stools of infants and young children. Despite its use, there is general agreement among paediatric gastroenterologists that the BSS is not adequate to be used in infants and young children who wear diapers; thus, a new scale specifically designed for this population is needed. Our aim is to develop a paediatric stool scale, the Brussels Infant and Toddler Stool Scale (`BITSS'), and to evaluate the interobserver agreement of stool assessment with the BITSS between the patient's parent and healthcare providers (physicians and nurses). Methods and analysis: This study has two phases. In the first phase, 11 key-opinion leaders in the field of paediatric gastroenterology representing different areas of the world selected seven coloured photographs of infants and/or young children wearing diapers to match the original descriptors of the BSS. The selected photographs were used to create a new scale in which the drawings of stools of the BSS were replaced by infant/toddlers stool photographs. In phase II, we aim at demonstrating that parents, nurses and primary healthcare physicians interpret the stool-pictures of the BITSS with a high degree of consensus and that the agreement is independent of whether it is a parent or a healthcare provider. Interobserver variability of stool assessment with the BITSS between the patient's parent and healthcare providers will be assessed. Ethics and dissemination: The study will be approved by the Ethics Committee of the participating centres. The findings of this study will be submitted to a peer-reviewed journal. Abstracts will be submitted to national and international conferences.
Dades de la publicació
- ISSN/ISSNe:
- 2044-6055, 2044-6055
- Tipus:
- Article
- Pàgines:
- -
- PubMed:
- 28360250
- Factor d'Impacte:
- 1,372 SCImago ℠
- Quartil:
- Q1 SCImago ℠
BMJ Open BMJ PUBLISHING GROUP
Cites Rebudes en Web of Science: 13
Documents
- No hi ha documents
Filiacions
Keywords
- *Bristol stool scale; *defecation; *stool
Projectes associats
ANALISIS DE NUEVOS GENES IMPLICADOS EN LA PATOGENESIS DE LA ENFERMEDAD CELIACA
Investigador Principal: CARMEN RIBES KONINCKX
PI02/0573 . INSTITUTO DE SALUD CARLOS III . 2004
INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP
Investigador Principal: CARMEN RIBES KONINCKX
643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015
NUEVA ESTRATEGIA PARA LA DERIVACIÓN DE HEPATOCITOS FUNCIONALES DE MUJERES AFECTAS DE DEFICIENCIA DE ORNITINA TRANSCARBAMILASA
Investigador Principal: BERNARDO ROQUE BORT MARTÍ
SAF2014-51991-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015
UN REGISTRO NO INTERVENCIONISTA A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES PEDIÁTRICOS CON ENFERMEDAD DE CROHN (EDC) ACTIVA ENTRE MODERADA Y GRAVE (CAPE).
Investigador Principal: ESTHER DONAT ALIAGA
P11-292 . 2015
ESTUDIO ABIERTO, MULTICÉNTRICO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV), CON O SIN DASABUVIR (DSV) Y CON O SIN RIBAVIRINA (RBV) EN PACIENTES PEDIÁTRICOS CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) GENOTIPO 1 O 4 (ZIRCON).
Investigador Principal: CARMEN RIBES KONINCKX
M14-748 . 2016
ESTUDIO DE SEGURIDAD Y CAPACIDAD NUTRICIONAL DE UNA NUEVA FORMULA HIPOALERGICA PARA LACTANTES CON DIVERSAS FORMAS DE ALERGIA A LAS PROTEINAS DE LA LECHE DE VACA.
Investigador Principal: CARMEN RIBES KONINCKX
HER-FHT-2009-01 . 2010
A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION. / ESTUDIO MULTICENTRICO, ALEATORIZADO, CONTR OLADO CON PLACEBO Y CON DOBLE ANONIMATO (DOBLE CIEGO) DE LA EFICACIA, SEGURIDAD Y FARMACOCINETICA DE LA LUBIPROSTONA EN PACIENTES PEDIATRICOS CON EDAD . 6 ANOS Y < 18 ANOS CON ESTRENIMIENTO FUNCIONAL.
Investigador Principal: CARMEN RIBES KONINCKX
SAG/0211PFC-1131
A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION./ ESTUDIO MULTICÉNTRICO A LARGO PLAZO SOBRE LA SEGURIDAD, LA EFICACIA Y LA FARMACOCINÉTICA DE L UBIPROSTONA EN PACIENTES PEDIÁTRICOS DE EDADES COMPRENDIDAS ENTRE >= 6 AÑOS Y < 18 AÑOS CON ESTREÑIMIENTO FUNCIONAL.
Investigador Principal: CARMEN RIBES KONINCKX
SAG/0211PFC-11S1 . 2015
ESTUDIO FARMACOEPIDEMIOLÓGICO PARA ESTABLECER EL PERFIL DE SEGURIDAD A LARGO PLAZO DE TENOFOVIR DISOPROXIL FUMARATO (TENOFOVIR DF, VIREAD®) Y DESCRIBIR EL TRATAMIENTO DE LA TOXICIDAD RENAL Y ÓSEA ASOCIADA A TENOFOVIR DF EN ADOLESCENTES DE 12 A <18 AÑOS CO N HEPATITIS B CRÓNICA (HBC) EN EUROPA.
Investigador Principal: CARMEN RIBES KONINCKX
GS-EU-174-1403 . 2015